For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Introduction Multiple myeloma (MM) is a malignancy derived from terminally differentiated plasma cells and has become the second most prevalent hematological cancer (1). Extramedullary disease (EMD) ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

After his cancer diagnosis, author and editor Jonathan Gluck was told he had 18 months left to live. Here’s what “almost ...

EXCLUSIVE: A top doctor has shared five common symptoms which could be a sign that something is seriously wrong.

An Essex mum left with holes in her spine after her cancer symptoms were put down to her pregnancy and post-partum recovery ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

SHANGHAI, June 19, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment ...